Home
OmniaBio

OmniaBio Market Share Analysis for August 2026

We provide commercial cell therapy manufacturing that supports your high-throughput program needs with timely QC and reliable delivery. Find out more!

Health > Biotechnology and Pharmaceuticals

Domainomniabio.com

Year Founded2006

Employees51 - 200

Annual Revenue--

OmniaBio

OmniaBio (including company regionals)

omniabio.com

See more website traffic and engagement information

Total visits to OmniaBio's top domains

Understand OmniaBio market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

omniabio.com5.7K

See more with Sales Intelligence

Avg. visit duration in OmniaBio's top domains

Analyze OmniaBio engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

omniabio.com00:00:02

See more with Sales Intelligence

Avg. pageviews on OmniaBio's top domains

See how OmniaBio keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

omniabio.com1.23

See more with Sales Intelligence

OmniaBio top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by OmniaBio

These are the website technologies, by industry, used by OmniaBio top domains

Marketing (5)

Google Marketing Platform

Audio Video Media (4)

YouTube

Conversion & Analytics (4)

Google Analytics

Advertising (3)

DoubleClick

More Technologies

9

See all

News & Signals from OmniaBio

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsOmniaBio Inc is developing AI-enabled "Intelligent Factory" on Jun 15th '26.Right now, OmniaBio is developing an AI-enabled "Intelligent Factory" to increase manufacturing efficiency, consistency, and scalability through automation and robotics.

NewsOmniaBio Inc partnered with Avectas Ltd. on Jun 15th '26.TORONTO, CANADA & DUBLIN IRELAND - June 15th, 2026 - CCRM and its CDMO subsidiary OmniaBio Inc., today announced an agreement with Avectas Limited ("Avectas") to evaluate its automated, integrated and scalable cell therapy manufacturing platform.

NewsOmniaBio Inc partnered with BrainChild Bio, Inc. on Oct 1st '25.TORONTO, ONTARIO & BOSTON, MA - October 1st, 2025 - OmniaBio Inc., a next generation contract development and manufacturing organization (CDMO) pioneering the manufacturing of cell and gene therapies (CGT) with robotics and artificial intelligence, and BrainChild Bio Inc, a clinical-stage biotechnology company developing Chimeric Antigen Receptor T-cell (CAR-T) therapies to treat solid tumors in the central nervous system, today announced their collaboration aimed at manufacturing BrainChild Bio's pivotal clinical trial therapeutic candidate BCB-276.